Activities of Marie-Christine BOUTONNET related to 2016/2057(INI)
Shadow opinions (1)
OPINION on EU options for improving access to medicines
Amendments (12)
Amendment 4 #
Draft opinion
Recital A
Recital A
A. whereas protection of health is a fundamental right enshringuaranteed inby the European Convention on Human RightMember States;
Amendment 13 #
Draft opinion
Recital B
Recital B
B. whereas EUMember States’ public budgets, including those covering health expenditure, are under significant constraints;
Amendment 19 #
Draft opinion
Recital D
Recital D
D. whereas competition based on smart protectionism can lower costs, reduce expenditure on medicines and improve access to affordable medicines;
Amendment 22 #
Draft opinion
Recital D a (new)
Recital D a (new)
Da. whereas the EU will need to oversee improvements in a range of fields that have an impact on how medicines are produced and distributed;
Amendment 35 #
Draft opinion
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Stresses the importance of observing the principle of subsidiarity, as each Member State must address any shortcomings on the basis of its own particular requirements;
Amendment 36 #
Draft opinion
Paragraph 1 b (new)
Paragraph 1 b (new)
1b. Calls for support for the progress achieved by the pharmaceutical industry, hitherto driven by European SMEs, which have transformed the standard of healthcare in Europe and helped to prolong life expectancy;
Amendment 37 #
Draft opinion
Paragraph 2
Paragraph 2
Amendment 46 #
Draft opinion
Paragraph 2 a (new)
Paragraph 2 a (new)
2a. Reiterates that part of the reason why businesses are becoming less competitive and why welfare spending is so high is that EU rules – including rules on drug pricing – are too burdensome;
Amendment 49 #
Draft opinion
Paragraph 3
Paragraph 3
Amendment 58 #
Draft opinion
Paragraph 4
Paragraph 4
Amendment 69 #
Draft opinion
Paragraph 5
Paragraph 5
5. Calls on the European Patent Office (EPO) and the Member States to grant patents on health products that strictly fulfil the patentability requirements of novelty, inventive step and industrial applicability as enshrined in the European Patent Convention;
Amendment 74 #
Draft opinion
Paragraph 6
Paragraph 6